RESPONSE RATE OF SOFOSBUVIR BASED ANTIVIRAL THERAPY AMONG PATIENTS INFECTED WITH HEPATITIS C VIRUS GENOTYPE 3A

Authors

  • Ijaz Ali Department of Biosciences, COMSATs University Islamabad - Pakistan.
  • Amina Gul Department of Pathology, Khyber Medical College Peshawar - Pakistan
  • Atika Noorul Sahar Department of Biosciences, COMSATs University Islamabad - Pakistan.
  • Shahid Niaz ``Khan Department of Zoology, Kohat University of Science and Technology Kohat - Pakistan.
  • Sadeequr Rahman College of Veterinary Sciences and AH, Abdul Wali Khan University Mardan - Pakistan
  • Imtiaz Ali Khan Department of Microbiology, The University of Swabi - Pakistan.
  • Johar Jamil Department of Microbiology, The University of Swabi - Pakistan.

Keywords:

HCV genotype 3a, Sofosbuvir, SVR12

Abstract

Objective: To evaluate the efficacy of dual therapy of Sofosbuvir and Ribavirin among treatment-naive and non-responders
of Interferon based antiviral regimens against HCV genotype 3a infected patients.
Material & Methods: A longitudinal study was conducted on 100 HCV genotype 3a infected patients from December
2016 to September 2017. Patients were initially divided into two groups including Group-A (n=50/100) as treatment
naive, and Group-B (n=50/100) including non-responders. All patients received Sofosbuvir and RBV for 24weeks. HCV
genotype was determined using Type-specific nested PCR based genotyping assay. Viral RNA was detected using
qualitative or real-time PCR.
Results: After 4 weeks of treatment, HCV RNA was undetectable in 100 of Group A patients, while Group B patients
achieved 92% RVR. SVR12 was 96% in treatment naïve Group A patients, while Group B patients achieved an SVR12 of
90%. There were no significant differences in the SVR12 rates between the two treatment groups (Pearson Chi-Square
test, p-value >0.05). The association of RVR and SVR12 was found statistically significant (Pearson Chi-Square test,
p- value<0.05).
Conclusion: Sofosbuvir and RBV is highly effective among the treatment-naive and previously treated chronic HCV
genotype 3a infected patients.

Downloads

Published

2019-12-29

How to Cite

Ali, I., Gul, A., Sahar, A. N., ``Khan, S. N., Rahman, S., Khan, I. A., & Jamil, J. (2019). RESPONSE RATE OF SOFOSBUVIR BASED ANTIVIRAL THERAPY AMONG PATIENTS INFECTED WITH HEPATITIS C VIRUS GENOTYPE 3A. Journal of Medical Sciences, 27(4), 295–301. Retrieved from https://jmedsci.com/Jmedsci/article/view/785

Issue

Vol. 27 No. 4 (2019): Contents

Section

Articles

License

All articles published in the Journal of Medical Sciences (JMS) are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0).  Under the CC BY 4.0 license, author(s) retain the ownership of the copyright publishing rights without restrictions for their content, and allow others to copy, use, print, share, modify, and distribute the content of the article even for commercial purposes as long as the original authors and the journal are properly cited.  No permission is required from the author/s or the publishers for this purpose.  Appropriate attribution can be provided by simply citing the original article. The corresponding author has the right to grant on behalf of all authors, a worldwide license to JMS and its licensees in all forms, formats, and media (whether known now or created in the future), The corresponding author must certify and warrant the authorship and proprietorship and should declare that he/she has not granted or assigned any of the article’s rights to any other person or body.

The corresponding author must compensate the journal for any costs, expenses, or damages that the JMS may incur as a result of any breach of these warranties including any intentional or unintentional errors, omissions, copyright issues, or plagiarism. The editorial office must be notified upon submission if an article contains materials like text, pictures, tables, or graphs from other copyrighted sources. The JMS reserves the right to remove any images, figures, tables, or other content, from any article, whether before or after publication, if concerns are raised about copyright, license, or permissions and the authors are unable to provide documentation confirming that appropriate permissions were obtained for publication of the content in question.